METASTATIC PANCREATIC ADENOCARCINOMA
Clinical trials for METASTATIC PANCREATIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PANCREATIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Pancreatic cancer radiation combo trial cut short
Disease control TerminatedThis study looked at whether adding a precise type of radiation (stereotactic body radiation therapy) to standard chemotherapy could better control pancreatic cancer that has spread to only a few spots in the body. The trial planned to enroll patients with limited metastases, but…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental combo shot for pancreatic cancer stalls after just 2 patients
Disease control TerminatedThis very early trial tested two immune-stimulating drugs injected directly into tumors for people with stage IV pancreatic cancer. The goal was to see if the combination could shrink tumors or slow their growth. However, the study was stopped early after enrolling only 2 partici…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New combo tackles pancreatic cancer resistance – but study halted early
Disease control TerminatedThis study tested whether combining two drugs, trametinib and hydroxychloroquine, could help overcome treatment resistance in people with advanced pancreatic cancer that had spread. The trial aimed to see how many patients were free of cancer growth after 12 weeks. It included 20…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental combo for tough pancreatic cancer shows early promise
Disease control TerminatedThis early-phase trial tested whether adding the experimental drug YL-13027 to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe for people with advanced pancreatic cancer that no longer responds to treatment. Only 4 participants were enrolled before the study was st…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Experimental pancreatic cancer combo trial halted early
Disease control TerminatedThis early-phase study tested whether adding the experimental drug NIS793 to standard chemotherapy (FOLFIRINOX) could help people with metastatic pancreatic cancer. Only 4 people took part before the study was stopped. The goal was to find a safe dose and see if the combination c…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Colin D. Weekes, M.D., PhD • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Experimental drug targets Hard-to-Treat cancers in new trial
Disease control TerminatedThis phase 2 trial tested a drug called tusamitamab ravtansine, alone or with chemotherapy (gemcitabine), in 50 people with advanced breast or pancreatic cancers that have a specific marker (CEACAM5). The goal was to see if the drug could shrink tumors. The study was terminated e…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC